Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

Rituximab 6fludarabine phosphate 3Vorinostat 3Specimen Handling 3Biopsy 3sargramostim 2ibrutinib 2binimetinib 2Sunitinib 2RFB4(dsFv)-PE38 recombinant immunotoxin 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2MK 2206 2Interferon-alpha 2Ifosfamide 2Flow Cytometry 2Etoposide 2Diphenhydramine 2Cladribine 2Carboplatin 2Bendamustine Hydrochloride 2B3(Fv)-PE38KDEL recombinant immunotoxin 2Analgesia 2Acetaminophen 2venetoclax 1veliparib 1tovorafenib 1tanespimycin 1obatoclax 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Hairy Cell × Caves × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡